MyFinsight
Home
Blog
About
Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$22,220K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Stock-based compensation expense
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts payable
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-29,886
-26,779
-20,440
-20,278
Stock-based compensation expense
6,842
6,553
3,826
3,306
Non-cash operating lease expense
492
489
491
490
Amortization of discount on marketable securities
157
200
353
836
Non-cash expense related to ipr&d acquisition
-
-
0
0
Depreciation expense
155
154
152
189
Prepaid expenses and other current assets
294
-740
1,539
-177
Accounts payable
-1,532
1,209
-712
567
Accrued expenses and other current liabilities
2,704
-3,463
2,492
1,684
Operating lease liabilities
-544
-543
-543
-529
Other assets
-
-
0
0
Net cash used in operating activities
-22,220
-21,840
-16,626
-15,230
Purchases of property and equipment
0
0
204
87
Purchases of marketable securities
33,031
25,327
42,878
54,136
Maturities of marketable securities
54,500
50,147
65,670
77,325
Net cash provided by (used in) investing activities
21,469
24,820
22,588
23,102
Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period
0
0
0
0
Proceeds from issuance of series c convertible preferred stock, net of issuance costs
-
-
0
0
Payment of deferred offering costs
230
320
0
0
Exercise of common stock options
979
2,213
1,659
1,974
Net cash provided by financing activities
749
1,893
1,659
1,974
Net increase in cash, cash equivalents and restricted cash
-2
4,873
7,621
9,846
Cash, cash equivalents and restricted cash at beginning of period
64,287
59,414
51,793
38,750
Cash, cash equivalents and restricted cash at end of period
64,285
-
-
-
Conversion of convertible preferred stock into common stock upon closing of initial public offering
0
-
-
-
Offering costs transferred to additional paid in capital
0
-
-
-
Deferred offering costs in accrued expenses and accounts payable
44
-
-
-
Proceeds receivable from stock option exercises
8
-
-
-
Cash and cash equivalents
63,322
-
-
-
Restricted cash
963
-
-
-
Total cash, cash equivalents, and restricted cash
64,285
64,287
59,414
51,793
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$54,500K
(-14.39%↓ Y/Y)
Exercise of common stock
options
$979K
(16216.67%↑ Y/Y)
Net cash provided by
(used in) investing...
$21,469K
(113.06%↑ Y/Y)
Net cash provided by
financing activities
$749K
(-99.63%↓ Y/Y)
Canceled cashflow
$33,031K
Canceled cashflow
$230K
Net increase in
cash, cash...
-$2K
(-100.06%↓ Y/Y)
Canceled cashflow
$22,218K
Stock-based compensation
expense
$6,842K
(38.67%↑ Y/Y)
Accrued expenses and
other current...
$2,704K
(222.85%↑ Y/Y)
Non-cash operating lease
expense
$492K
(-49.85%↓ Y/Y)
Depreciation expense
$155K
(-49.35%↓ Y/Y)
Purchases of marketable
securities
$33,031K
(-85.51%↓ Y/Y)
Payment of deferred
offering costs
$230K
Net cash used in
operating activities
-$22,220K
(35.48%↑ Y/Y)
Canceled cashflow
$10,193K
Net loss
-$29,886K
(13.50%↑ Y/Y)
Accounts payable
-$1,532K
(-463.24%↓ Y/Y)
Operating lease
liabilities
-$544K
(48.48%↑ Y/Y)
Prepaid expenses and
other current assets
$294K
(-59.17%↓ Y/Y)
Amortization of discount on
marketable securities
$157K
(-91.57%↓ Y/Y)
Buy us a coffee